Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioMimetic Therapeutics

Request full access

Provider of orthopedic consultation and health care to patients

Round Rock, United StatesFounded 1999Biotech & Life Sciences

About BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. operated as a biotechnology firm focused on developing and commercializing drug-device combination products for musculoskeletal healing. The company was founded in 1999 by Dr. Samuel E. Lynch, a scientist and entrepreneur with doctorates from Harvard Medical School who pioneered research in regenerative medicine. Dr. Lynch identified the therapeutic potential of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) and led the company from its inception, through an initial public offering, to its eventual strategic sale.

The company's core business involved creating biologically active products to regenerate bone and associated tissues for orthopedic, spine, and sports injury applications. Its flagship product, Augment® Bone Graft, was developed as a synthetic alternative to autograft, the practice of harvesting a patient's own bone for grafting procedures. Augment combines rhPDGF-BB, which stimulates cell growth and proliferation, with a beta-tricalcium phosphate (β-TCP) scaffold that provides a framework for new bone formation. This approach was designed to offer comparable healing outcomes while eliminating the need for a second, often painful, surgery to harvest bone graft material. The company's business model relied on securing regulatory approvals and then marketing these products to surgeons and medical facilities. BioMimetic successfully gained marketing approval for Augment® in Canada, Australia, and New Zealand.

A significant milestone in the company's history was its acquisition by Wright Medical Group, Inc., an orthopedics company, in a deal announced in November 2012 and completed on March 1, 2013. The transaction was valued at a potential total of approximately $380 million, including an upfront payment of $190 million in cash and stock, plus additional milestone-based payments. The acquisition combined BioMimetic's biologics platform with Wright Medical's established sales force and extremities product portfolio, aiming to accelerate the market adoption of Augment®. Following the acquisition, the FDA approved Augment® Bone Graft in September 2015 for use in ankle and hindfoot fusion procedures. BioMimetic Therapeutics ceased to exist as an independent, publicly traded entity (NASDAQ: BMTI) and became a wholly owned subsidiary.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
6
Open positions
None listed
Dealroom signal
23.3/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Patient Care, Spinout, Orthopedic, Biotech and Pharma, DT and LS, science-based
Client focus
B2C

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Nov 2012 $190M $190M Wright Medical Group —
EARLY VCOther financing Jun 2009 $2.9M $12M Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

BioMimetic Therapeutics website traffic

Latest recorded traffic for BioMimetic Therapeutics is 280 monthly website visits.

Latest monthly visits280
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

BioMimetic Therapeutics in the Round Rock ecosystem

Live from Dealroom

The BioMimetic Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Holden Capital
  • Burrill
  • Novo Holdings
  • MB Venture Partners

Series B and later6 investors entered at this stage

  • InterWest Partners
  • Mitsubishi
  • PTV Healthcare Capital
  • Noro-Moseley Partners
  • Axiom Ventures
  • Knowledge Ventures

Other known investors3 additional known investors

  • Harvard School of Dental Medicine
  • Harvard University
  • Wright Medical Group
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Round Rock HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioMimetic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioMimetic Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.